Spire Wealth Management Has $6.05 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Spire Wealth Management grew its position in Edwards Lifesciences Co. (NYSE:EW) by 40.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 81,351 shares of the medical research company’s stock after buying an additional 23,278 shares during the period. Spire Wealth Management’s holdings in Edwards Lifesciences were worth $6,045,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $34,000. Operose Advisors LLC boosted its position in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. bought a new stake in Edwards Lifesciences in the third quarter valued at about $52,000. Finally, ORG Partners LLC acquired a new position in Edwards Lifesciences in the third quarter valued at about $66,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on EW shares. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Finally, Royal Bank of Canada raised their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Edwards Lifesciences Stock Down 0.2 %

NYSE EW traded down $0.16 during trading on Monday, hitting $85.09. The stock had a trading volume of 2,449,647 shares, compared to its average volume of 3,757,333. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company’s 50-day moving average price is $90.08 and its two-hundred day moving average price is $79.46. The company has a market capitalization of $51.28 billion, a PE ratio of 36.68, a P/E/G ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insiders Place Their Bets

In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold 237,749 shares of company stock valued at $20,920,934 in the last three months. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.